Check patentability & draft patents in minutes with Patsnap Eureka AI!

Crystalline polymorph of pipindoxifene hydrochloride monohydrate

A polymorph, monohydrate technology, applied in the field of selective estrogen receptor modulators

Inactive Publication Date: 2007-07-04
WYETH LLC
View PDF4 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, finding therapeutically promising drugs for cancers known to involve estrogen receptor function and dysfunction is challenging

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline polymorph of pipindoxifene hydrochloride monohydrate
  • Crystalline polymorph of pipindoxifene hydrochloride monohydrate
  • Crystalline polymorph of pipindoxifene hydrochloride monohydrate

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0033] Examples of the preparation of Forms I and II are provided in the Examples. Generally, the polymorph product is released from the solvent by dissolving piridoxifene hydrochloride (any form, including amorphous) in a suitable aqueous solvent and by any conventional method known in the art, such as cooling or evaporating the solvent. Crystallization, Form I can be prepared. Suitable solvents include mixtures of water, alcohols and optionally ethers. The water content of the solvent appeared to affect the relative amounts of Form I and Form II that precipitated. A higher content of water in the solvent favors Form II while a low content of water favors Form I.

[0034] In the preparation of Form II, the volume ratio of water to alcohol in the crystallization solvent may be greater than about 1:5. In some embodiments, the volume ratio of water to alcohol in the preparation of Form II is about 2 to about 1:5, about 1 to about 1:5, about 1:2 to about 1:5, about 2:5 to abo...

Embodiment 1

[0062] Preparation of piridoxifene hydrochloride monohydrate crystal form I

[0063] Into a 1 L three-necked flask equipped with a mechanical stirrer, temperature probe, reflux condenser and nitrogen atmosphere were charged 150 g of piridoxifene hydrochloride, 1035 g, 1312 mL of pre-filtered ethanol and 188 g of purified water. The mixture was heated to 78-80°C over a minimum of 45 minutes to form a solution. The resulting solution was stirred at moderate speed at 80°C for 15 minutes. The stirring speed was reduced to 75 rpm and the solution was allowed to cool to 22-25°C within 5 hours. Crystallization started at 65-67°C. The slurry was maintained at 22-25°C for at least 1 hour before solids were collected by filtration on a 12.5 cm Buchner funnel with filter paper. The filter cake was washed with ethanol (118 g / 150 mL, pre-filtered and pre-cooled to 10-15 °C). The filter cake was then drained until dripping ceased, at which point it had a depth of 1.6 cm. The filter cak...

Embodiment 2

[0065] Method for preparing piridoxifene hydrochloride monohydrate crystal form II from crystal form I

[0066] Into a 1 L three-necked flask equipped with a mechanical stirrer, temperature probe, reflux condenser and nitrogen atmosphere, 20 g of a sample of piridoxifene hydrochloride Form I, 280 mL of ethanol and 120 mL of purified water were added. The material introduced into the flask showed a DSC peak at 188°C, indicating Form I. The mixture was heated to reflux temperature to dissolve the piridoxifene. The mixture was cooled to 22°C over 3 hours and a visible slurry formed. The mixture was filtered and the precipitate was washed with 20 mL of cold ethanol. The product was dried in a vacuum oven at 40° C. for 2 hours and then at room temperature for a further 22 hours. DSC scan revealed a new polymorph (Form II) with a peak at 179°C. See Example 6 for the DSC method. The product yield was 74%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a crystalline polymorph of pipindoxifene hydrochloride monohydrate, compositions containing the same, preparations thereof, and uses thereof.

Description

field of invention [0001] The present invention relates to selective estrogen receptor modulators, 2-(4-hydroxyphenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl] - a crystalline polymorph of 1H-indole-5-ol hydrochloride (pipindoxifene hydrochloride), referred to as Form I. Background of the invention [0002] Pirdoxifene hydrochloride (2-(4-hydroxyphenyl)-3-methyl-1-[4-(2-piperidin-1-ylethoxy)-benzyl]-1H-indole -5-ol hydrochloride) has the chemical formula shown below. [0003] [0004] The compound belongs to the class of drugs generally known as selective estrogen receptor modulators (SERMs). Consistent with its classification, piridoxifene demonstrated affinity for the estrogen receptor (ER), but no tissue-selective estrogenic effects, eg, little or no uterotropic activity. [0005] Piridoxifene is a variant of zinidoxifene and ZK119010 (Von Angerer et al., J. Med. Chem. 33:2635-2640 (1990) and Von Angerer et al., J. Med. Chem. (1984) 27 : 1439-1447). It has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D209/12A61K31/404
CPCC07D401/12C07D209/12A61P15/12A61P15/14A61P19/08A61P35/00A61P43/00A61P5/30A61P5/32
Inventor C·德默森G·奇尔
Owner WYETH LLC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More